📰 Acticor News
Page 3 - Acticor News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acticor. Real-time updates on events, politics, business and more.
March 8, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company specialized in developing innovative treatments for cardiovascular emergencies
February 2, 2022
Regulatory News: Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announced today the results of
January 13, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies
January 13, 2022
pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority (AMF Autorité des Marchés Financiers) Regulatory
November 4, 2021
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces that the U.S Food and Drug
October 30, 2021
Organized by the prestigious Galien Foundation and Business France, the Prix Galien Medstartup rewards the best Franco-American collaborations in the pharmaceutical sector. ACTICOR BIOTECH